Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I): or a pharmaceutically acceptable salt, or ester thereof, wherein R1 and R2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C1-C6 alkyl groups, with the proviso that R1 and R2 are not both hydrogen or a pharmaceutically acceptable salt or ester thereof. Such diseases or conditions may relate to coronary heart disease (CHD), for example atherosclerosis； metabolic syndrome/insulin resistance； and/or a dyslipidemic condition such as hypertriglyceridemia (HTG), elevated LDL-cholesterol, elevated total-cholesterol, elevated Apo B and low HDL-cholesterol. The present disclosure further provides for a method of reducing atherosclerosis development. Pharmaceutical compositions comprising a compound of Formula (I) are also disclosed.本揭露關於對需要治療或預防至少一種疾病或症狀之個體治療或預防該等疾病或症狀之方法，其包含給予式(I)化合物：或彼之醫藥上可接受之鹽或酯，其中R1和R2各別選自氫原子或直鏈、支鏈及/或環狀C1-C6烷基，唯R1和R2不皆為氫。該等疾病或症狀可關於冠狀心臟疾病(CHD；例如動脈粥樣硬化)、代謝徵候/胰島素抗性、及/或血脂異常症狀(諸如高三酸甘油脂血症(HTG)、升高之LDL-膽固醇、升高之總膽固醇、升高之Apo B及低HDL-膽固醇)。本揭露進一步提供一種減緩動脈粥樣硬化發展之方法。亦揭露包含式(I)化合物之醫藥組成物。
